title: Biologics inch toward cholesterol-lowering market.
authors.forename: Ken
authors.initials: K
authors.lastname: Garber
mesh_terms: D017326:Clinical Trials, Phase III as Topic / Q000191:economics; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D006937:Hypercholesterolemia / Q000191:economics* / Q000628:therapy; D008077:Lipoproteins, LDL / Q000191:economics; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000191:economics* / Q000627:therapeutic use; D012697:Serine Endopeptidases / Q000191:economics* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D008077:Lipoproteins, LDL; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases